Why the study?
Do xanthates and trithiocarbonates inhibit carbonic anhydrases and lower intraocular pressure in animal models of glaucoma?
Do xanthates and trithiocarbonates inhibit carbonic anhydrases and lower intraocular pressure in animal models of glaucoma?
Xanthates and trithiocarbonates represent novel classes of carbonic anhydrase inhibitors with potential as antiglaucoma agents.
Answers are grounded in this paper and cite their sources.
May support xanthate development as topical glaucoma therapy; leaves open human efficacy and safety.
Dithiocarbamates (DTCs) were recently discovered as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors. A series of xanthates and a trithiocarbonate, structurally related to the DTCs, were prepared by reaction of alcohols/thiols with carbon disulfide in the presence of bases. These compounds were tested for the inhibition of four human (h) isoforms, hCA I, II, IX, and XII, involved in pathologies such as glaucoma (CA II and XII) or cancer (CA IX). Several low nanomolar xanthate/trithiocarbonate inhibitors targeting these CAs were detected. A docking study of some xanthates within the CA II active site showed that these compounds bind in a similar manner with the dithiocarbamates, coordinating monodentately to the Zn(II) ion from the enzyme active site. Several xanthates showed potent intraocular pressure lowering activity in two animal models of glaucoma via the topical administration. Xanthates and thioxanthates represent two novel, promising classes of CA inhibitors.
No takes yet. Share an insight, caveat, or question.
Carta et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: